Compare Stocks: SNOA, NEUP, TVRD, and KZIA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KZIA Novogen	$12.00 -2.5%	$13.06	$4.86 ▼ $17.40	$19.80M	2.16	211,620 shs	233,027 shs
NEUP Neuphoria Therapeutics	$3.95 +1.5%	$4.11	$3.19 ▼ $21.40	$21.33M	0.75	110,901 shs	40,901 shs
SNOA Sonoma Pharmaceuticals	$1.13 -5.8%	$1.17	$0.85 ▼ $6.92	$5.41M	1.28	118,843 shs	154,032 shs
TVRD Tvardi Therapeutics	$2.00 -1.5%	$2.70	$1.50 ▼ $43.65	$18.76M	0.39	1.01 million shs	325,306 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KZIA Novogen	-0.81%	-2.99%	-7.09%	-11.05%	+47.60%
NEUP Neuphoria Therapeutics	-1.02%	+2.10%	+15.09%	-27.70%	-50.00%
SNOA Sonoma Pharmaceuticals	+7.14%	+5.26%	-0.83%	+0.84%	-61.17%
TVRD Tvardi Therapeutics	+0.50%	-16.80%	+0.50%	-44.54%	-92.29%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KZIA Novogen	$12.00 -2.5%	$13.06	$4.86 ▼ $17.40	$19.80M	2.16	211,620 shs	233,027 shs
NEUP Neuphoria Therapeutics	$3.95 +1.5%	$4.11	$3.19 ▼ $21.40	$21.33M	0.75	110,901 shs	40,901 shs
SNOA Sonoma Pharmaceuticals	$1.13 -5.8%	$1.17	$0.85 ▼ $6.92	$5.41M	1.28	118,843 shs	154,032 shs
TVRD Tvardi Therapeutics	$2.00 -1.5%	$2.70	$1.50 ▼ $43.65	$18.76M	0.39	1.01 million shs	325,306 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KZIA Novogen	-0.81%	-2.99%	-7.09%	-11.05%	+47.60%
NEUP Neuphoria Therapeutics	-1.02%	+2.10%	+15.09%	-27.70%	-50.00%
SNOA Sonoma Pharmaceuticals	+7.14%	+5.26%	-0.83%	+0.84%	-61.17%
TVRD Tvardi Therapeutics	+0.50%	-16.80%	+0.50%	-44.54%	-92.29%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KZIA Novogen	2.67	Moderate Buy	$25.80	115.99% Upside
NEUP Neuphoria Therapeutics	2.00	Hold	$21.00	446.88% Upside
SNOA Sonoma Pharmaceuticals	1.00	Sell	N/A	N/A
TVRD Tvardi Therapeutics	2.78	Moderate Buy	$18.00	854.91% Upside

Current Analyst Ratings Breakdown

Latest SNOA, NEUP, TVRD, and KZIA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2026	TVRD Tvardi Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$5.00
7/24/2026	SNOA Sonoma Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	KZIA Novogen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	KZIA Novogen	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$34.00
7/8/2026	TVRD Tvardi Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/8/2026	TVRD Tvardi Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Outperform	$10.00
7/8/2026	TVRD Tvardi Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$13.00
7/8/2026	TVRD Tvardi Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$10.00
7/7/2026	TVRD Tvardi Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$15.00
7/1/2026	KZIA Novogen	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$34.00
6/11/2026	KZIA Novogen	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$32.00

(Data available from 8/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KZIA Novogen	$30K	656.98	N/A	N/A	($5.34) per share	-2.24
NEUP Neuphoria Therapeutics	$15.65M	1.32	$0.15 per share	25.22	$10.11 per share	0.38
SNOA Sonoma Pharmaceuticals	$19.53M	0.29	N/A	N/A	$0.65 per share	1.83
TVRD Tvardi Therapeutics	$7.14M	2.48	N/A	N/A	$2.23 per share	0.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KZIA Novogen	-$13.41M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/4/2026 (Estimated)
NEUP Neuphoria Therapeutics	-$370K	-$11.06	N/A	N/A	N/A	N/A	-76.93%	-54.76%	9/2/2026 (Estimated)
SNOA Sonoma Pharmaceuticals	-$3.17M	-$1.89	N/A	N/A	N/A	-16.26%	-43.95%	-11.27%	8/6/2026 (Estimated)
TVRD Tvardi Therapeutics	-$18.21M	-$3.10	N/A	N/A	N/A	N/A	-64.17%	-43.90%	N/A

Latest SNOA, NEUP, TVRD, and KZIA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/2/2026	Q4 2026	NEUP Neuphoria Therapeutics	-$0.56	N/A	N/A	N/A	N/A	N/A
8/6/2026	N/A	SNOA Sonoma Pharmaceuticals	-$0.30	N/A	N/A	N/A	$4.99 million	N/A
6/16/2026	Q4 2026	SNOA Sonoma Pharmaceuticals	-$0.24	-$0.33	-$0.09	-$0.33	$5.57 million	$5.56 million
5/15/2026	Q3 2026	NEUP Neuphoria Therapeutics	-$0.56	-$0.09	+$0.47	-$0.09	N/A	N/A
5/8/2026	Q1 2026	TVRD Tvardi Therapeutics	-$0.65	-$0.73	-$0.08	-$0.73	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
KZIA Novogen	N/A	N/A	N/A	N/A	N/A
NEUP Neuphoria Therapeutics	N/A	N/A	N/A	N/A	N/A
SNOA Sonoma Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TVRD Tvardi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KZIA Novogen	N/A	2.87	N/A
NEUP Neuphoria Therapeutics	N/A	14.31	14.31
SNOA Sonoma Pharmaceuticals	N/A	2.50	1.75
TVRD Tvardi Therapeutics	N/A	2.25	2.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KZIA Novogen	30.89%
NEUP Neuphoria Therapeutics	15.90%
SNOA Sonoma Pharmaceuticals	1.95%
TVRD Tvardi Therapeutics	44.66%

Insider Ownership

Company	Insider Ownership
KZIA Novogen	1.00%
NEUP Neuphoria Therapeutics	1.50%
SNOA Sonoma Pharmaceuticals	1.02%
TVRD Tvardi Therapeutics	7.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KZIA Novogen	12	1.65 million	1.64 million	No Data
NEUP Neuphoria Therapeutics	N/A	5.40 million	5.32 million	N/A
SNOA Sonoma Pharmaceuticals	180	4.79 million	4.74 million	Not Optionable
TVRD Tvardi Therapeutics	80	9.38 million	8.69 million	N/A

SNOA, NEUP, TVRD, and KZIA Headlines

Recent News About These Companies

BTIG Research Has Lowered Expectations for Tvardi Therapeutics (NASDAQ:TVRD) Stock Price

August 1, 2026 | americanbankingnews.com

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109, Plans 2027 Clinical Trial

July 30, 2026 | quiverquant.comQ

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

July 30, 2026 | globenewswire.com

Tvardi Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:TVRD

July 23, 2026 | benzinga.com

Tvardi Therapeutics Inc TVRD

July 14, 2026 | morningstar.comM

Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD), Teva Pharmaceutical (TEVA) and BridgeBio Pharma (BBIO)

July 10, 2026 | theglobeandmail.com

TVRD Stock Rallies 149% So Far This Week: Here's What You Should Know

July 9, 2026 | zacks.com

Tvardi Therapeutics Reports Phase 1 Data for TTI-109

July 8, 2026 | theglobeandmail.com

Tvardi Therapeutics (Nasdaq: TVRD) Soars on Positive Phase 1 Results for Next-Gen STAT3 Inhibitor TTI-109

July 7, 2026 | investorideas.comI

Tvardi Therapeutics Inc.

July 7, 2026 | cnn.com

Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement

July 7, 2026 | finance.yahoo.com

Tvardi Therapeutics' TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement

July 7, 2026 | globenewswire.com

TVRD Share News Today

June 29, 2026 | uk.investing.com

Tvardi Therapeutics Sets Key Deadlines for 2026 Meeting

June 27, 2026 | theglobeandmail.com

Tvardi Therapeutics, Inc. Common Stock

June 27, 2026 | fxempire.comF

H.C. Wainwright Initiates a Buy Rating on Tvardi Therapeutics (TVRD)

June 25, 2026 | theglobeandmail.com

Tvardi Therapeutics Shareholders Approve Directors and Governance Measures

June 11, 2026 | tipranks.com

Tvardi Therapeutics to Participate in Upcoming Investor Events

May 21, 2026 | globenewswire.com

Oppenheimer Sticks to Its Buy Rating for Tvardi Therapeutics (TVRD)

May 13, 2026 | theglobeandmail.com

Tvardi Therapeutics (TVRD) Receives a Buy from BTIG

May 11, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNOA, NEUP, TVRD, and KZIA Company Descriptions

Novogen NASDAQ:KZIA

$12.00 -0.31 (-2.52%)

Closing price 04:00 PM Eastern

Extended Trading

$11.97 -0.03 (-0.25%)

As of 04:49 PM Eastern

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Neuphoria Therapeutics NASDAQ:NEUP

$3.95 +0.06 (+1.54%)

Closing price 04:00 PM Eastern

Extended Trading

$3.94 -0.01 (-0.25%)

As of 04:10 PM Eastern

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Sonoma Pharmaceuticals NASDAQ:SNOA

$1.13 -0.07 (-5.83%)

Closing price 04:00 PM Eastern

Extended Trading

$1.12 -0.01 (-1.33%)

As of 04:48 PM Eastern

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

Tvardi Therapeutics NASDAQ:TVRD

$2.00 -0.03 (-1.48%)

Closing price 04:00 PM Eastern

Extended Trading

$2.01 +0.01 (+0.50%)

As of 04:10 PM Eastern

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SNOA, NEUP, TVRD, and KZIA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SNOA, NEUP, TVRD, and KZIA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SNOA, NEUP, TVRD, and KZIA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNOA, NEUP, TVRD, and KZIA Company Descriptions

Novogen NASDAQ:KZIA

Neuphoria Therapeutics NASDAQ:NEUP

Sonoma Pharmaceuticals NASDAQ:SNOA

Tvardi Therapeutics NASDAQ:TVRD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SNOA, NEUP, TVRD, and KZIA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SNOA, NEUP, TVRD, and KZIA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SNOA, NEUP, TVRD, and KZIA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNOA, NEUP, TVRD, and KZIA Company Descriptions

Novogen NASDAQ:KZIA

Neuphoria Therapeutics NASDAQ:NEUP

Sonoma Pharmaceuticals NASDAQ:SNOA

Tvardi Therapeutics NASDAQ:TVRD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools